CPRXNEUTRAL

EV/EBITDA

10.1x

Higher than 42% of Healthcare sector peers

Updated 167h ago

Sector Performance

42th percentile

CPRX

10.1x

Sector Median

12.8x

Sector Avg

15.6x

📊

Deep Analysis

Catalyst Pharmaceuticals currently trades at an EV/EBITDA of 10.1x, meaning its enterprise value (market cap plus debt minus cash) is 10.1 times its earnings before interest, taxes, depreciation, and amortization—a common gauge of valuation.

This sits below the healthcare sector median of 13.1x, placing the company in the 35th percentile among its peers, indicating it is cheaper than most. No year-over-year or quarter-over-quarter change data is available, and no trend direction over the last eight quarters can be assessed. The combination of a below-median valuation with no established trend suggests limited immediate mispricing signals; the discount could reflect lower growth expectations or a risk premium, but without a trend, it neither confirms a buying opportunity nor a warning. This metric supports the overall NEUTRAL verdict—the valuation is modestly attractive relative to peers, but the absence of trajectory data prevents drawing a bullish or bearish conclusion.

Frequently Asked Questions

What does the EV/EBITDA tell investors about CPRX?

A valuation multiple preferred by analysts for capital-intensive or leveraged businesses. Useful for cross-sector comparisons where earnings can be distorted by debt.

How is the EV/EBITDA calculated?

EV/EBITDA is calculated as: Enterprise Value / EBITDA.

How does CPRX's EV/EBITDA compare to its sector?

CPRX's EV/EBITDA of 10.1x compares to a Healthcare sector median of 12.8x, placing it in the 42th percentile.

Who are CPRX's closest peers by EV/EBITDA?

The closest Healthcare peers by EV/EBITDA include: BDX (12.2x), GSK (10.2x), ZBH (9.7x), BAX (9.4x), BIIB (8.8x).

The Formula

Enterprise Value / EBITDA

Why It Matters

A valuation multiple preferred by analysts for capital-intensive or leveraged businesses. Useful for cross-sector comparisons where earnings can be distorted by debt.